CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.

MLA

Park, Sang Hyuk, et al. “CEBPA Single Mutation Can Be a Possible Favorable Prognostic Indicator in NPM1 and FLT3-ITD Wild-Type Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk.” Leukemia Research, vol. 37, no. 11, Nov. 2013, pp. 1488–94. EBSCOhost, https://doi.org/10.1016/j.leukres.2013.08.014.

APA

Park, S. H., Chi, H.-S., Cho, Y.-U., Jang, S., & Park, C.-J. (2013). CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk. Leukemia Research, 37(11), 1488–1494. https://doi.org/10.1016/j.leukres.2013.08.014

Chicago

Park, Sang Hyuk, Hyun-Sook Chi, Young-Uk Cho, Seongsoo Jang, and Chan-Jeoung Park. 2013. “CEBPA Single Mutation Can Be a Possible Favorable Prognostic Indicator in NPM1 and FLT3-ITD Wild-Type Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk.” Leukemia Research 37 (11): 1488–94. doi:10.1016/j.leukres.2013.08.014.